1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CDT Equity Inc.

CDT Equity Inc.

CDTTW
CDT Equity Inc.US flagNASDAQ Capital Market
0.01
USD
+0.00
- -
14,016.00Market Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
2
2
Net Income, GAAP
-4
-5
-1
-18
-39
-39
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
-2
-4
4
-8
-8
-8
LT Debt
1
2
- -
- -
- -
- -
Total Equity
-6
-10
- -
-7
-7
-7
Return on Invested Capital (%)
- -
- -
139.37
- -
- -
- -
Return on Capital (%)
- -
- -
3.4
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
2
2
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
6
7
4
Cash, Cash Equivalents & STI
3
4
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
13
Payables & Accruals
2
2
12
ST Debt
2
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
5.55%
Free Cash Flow
- -
- -
84.51%
Net Income, GAAP
- -
- -
120.33%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Andrew Regan
Full Time Employees
6
Sector
Healthcare
Industry
Biotechnology
Address
4581 Tamiami Trail North Naples FL United States of America 34103
IPO Date
Mar 28, 2022
CIK
0001896212
Website
conduitpharma.com
Similar Companies
Alligator Bioscience AB (publ) (ATORX.ST)
Citius Pharmaceuticals Inc (CTXRW)
ABVC BioPharma, Inc. (ABVC)
Lunai Bioworks Inc. (LNAI)
Aligos Therapeutics, Inc. (ALGS)
Ligand Pharmaceuticals Incorporated (LGNDV)
Business
CDT Equity Inc. (NASDAQ: CDT, CDTTW) is a clinical-stage biopharmaceutical company that identifies, enhances and advances high-potential therapeutic assets through artificial intelligence, solid-form chemistry and strategic partnerships; its pipeline targets autoimmune disorders including uveitis and Hashimoto's thyroiditis, idiopathic male infertility, oncology, dermatology and animal health with candidates such as AZD1656, a glucokinase activator that has completed Phase I trials, and AZD5904; the company employs co-crystallization technologies at its Cambridge, UK facilities to improve drug properties and extend patent life by up to 20 years, alongside AI-driven disease mapping for repurposing deprioritized clinical compounds. Founded in 2019 and headquartered in Naples, Florida, CDT Equity operates a lean, disease-agnostic model focused on in vitro and in vivo studies to support licensing deals and commercialization partnerships with third parties, while serving human and animal health markets through efficient asset repositioning. Originally established as Conduit Pharmaceuticals Inc., the company rebranded as CDT Equity in 2024 to reflect its expanded platform; recent developments include strategic partnerships with Sarborg for AI disease mapping, Manoira for animal health insights, and Agility Life Sciences for solid oral-dosage formulations, alongside a cryptocurrency treasury strategy featuring acquisitions of approximately 17.9 bitcoin as of October 2025, a 1-for-8 reverse stock split effective October 2025 and identification of new biological targets validating its AI repurposing approach.